Mutations in the human SLC26A4/Pendrin polypeptide (hPDS) cause Pendred Syndrome /DFNB4, syndromic deafness with enlargement of the vestibular aqueduct and low-penetrance goiter. Here we present data on cloning, protein overexpression and purification, refolding, and biophysical characterization of the recombinant hPDS STAS domain lacking its intrinsic variable sequence (STAS-ΔIVS). We report a reproducible protein refolding protocol enabling milligram scale expression and purification of uniformly 
Introduction
SLC26 family anion transport proteins are conserved throughout phylogeny from bacteria to humans [1, 2] . In prokaryotes and plants this family of proteins is known as SulP (Sulfate Permease). SLC26 and SulP proteins consist of a short cytoplasmic N-terminus, a complex polytopic transmembrane domain of 14 trans-bilayer spans, and a cytoplasmic C-terminal region of 125-250 aa largely comprizing a Sulfate Transporter and anti-Sigma factor antagonist (STAS) domain [3] . The 10 known protein-coding human SLC26 genes encode anion transporters, exchangers and channels expressed in epithelial cells and other cell types throughout the body. Mutations in at least four human SLC26 genes cause early-onset Mendelian diseases, including chondrodysplasia (SLC26A2/DTD), chloride-losing diarrhea (SLC26A3/DRA), deafness with enlargement of the vestibular aqueduct and low-penetrance goiter (SLC26A4/ pendrin), and a rare form of impaired male fertility (SLC26A8). Many of these mutations involve the respective STAS domains. The human disease phenotypes are modeled in knockout mice with varying degrees of clinical fidelity, and genetic inactivation in mice of other Slc26 genes unassociated as yet with human disease also causes pathogenic murine phenotypes. In addition, human SLC26A9 variants have been identified as strong risk modifiers of cystic fibrosis lung disease, whereas human pendrin (hPDS/SLC26A4) has been investigated as a risk modifier of systemic fluid balance, blood pressure, and asthma [2] .
The STAS domains of SLC26/SulP transporters are homologous to bacterial anti-sigma factor antagonists such as SpoIIAA of B. subtilis [4, 5] . Anti-sigma factor antagonists counter the activity of repressors (anti-sigma factors) of sigma (transcription) factors in the bacterial sporulation stress response pathway [6] . STAS domains are essential for plasmalemmal targeting, contribute to anion transport function and, like bacterial anti-sigma factors, serve as protein-protein interaction modules. Mutations in STAS domains of mammalian SLC26 transporters and bacterial SulP transporters impair function and/or surface expression of these transporters [3, 7, [8] [9] [10] .
SpoIIAA-like STAS domain structures solved by X-ray crystallography include those from dicarboxylate and bicarbonate transporter [11, 12] , DauA(YchM) of E. coli [13] and from dicarboxylate transporter SLC26Dg [3] , as well as a STAS-ΔIVS structure from the cochlear outer hair cell Cl-dependent amplifier SLC26A5/prestin of rat [14] . NMR solution structures have been solved for rat prestin STAS-ΔIVS [14] and for the intact putative sulfate transporter Rv1739c of M. tuberculosis [15] . The presence of the unstructured "intervening sequence" (IVS) located between STAS helices α1 and β3 (nomenclature from [14] ) distinguishes mammalian and metazoan STAS domains from those of bacterial anti-sigma factor antagonists and SulP transporters. No function has yet been reported for the IVS, and its deletion was required for protein overexpression and production of the first STAS domain crystals diffracting to high resolution [14] . All mammalian STAS domains reported subsequently have lacked the IVS, and along with bacterial STAS domains have yielded monomeric solution structures. Two-dimensional 1 H-15 N HSQC spectra of wildtype and mutant STAS from human SLC26A3/DRA have been presented without NMR assignment [8] .
In addition to their enabling contributions to SLC26-mediated anion transport, SulP STAS domains are also nucleotide binding proteins [12, 15] , as previously demonstrated for SpoIIAA and ASAs [4, 5] . Mammalian STAS domains have been shown to interact with multiple proteins in pulldown assays, including CFTR [8] , OASTL (for A. thaliana Sultr1) [16] and IQGAP-1 [11] . Towards an understanding of the structural basis and functional utility of STAS domain nucleotide binding, we have initiated a structural characterization of the hPDS/SLC26A4 STAS domain by heteronuclear solution NMR, both in the absence and presence of the IVS. Here we present data on the molecular cloning, purification, and preliminary structural characterization of recombinant hPDS STAS domain lacking the IVS region (STAS-ΔIVS). The reported purification strategy yields well-folded hPDS STAS-ΔIVS in quantities and of stability sufficient for structural characterization by solution NMR. We also report biophysical experiments that demonstrate nucleotide binding by hPDS STAS-ΔIVS.
Materials and methods

Molecular cloning of recombinant hPDS STAS domain (ΔIVS)
To delimit operational boundaries of the STAS domain of SLC26A4/hPDS (Uniprot # O43511), the aa sequence of hPDS STAS was aligned with STAS domains of other human SLC26 polypeptides and with other structurally characterized STAS domains [5, 17] . The secondary structure of hPDS STAS was predicted using Psipred (http://bioinf.cs.ucl.ac.uk/psipred/). These analyses suggested a STAS domain encompassing aa residues 517-734, with aa 575-652 as the IVS region. Initial hPDS STAS-ΔIVS constructs encompassing aa 512-780 (hPDS L STAS-ΔIVS) and aa 512-743 (hPDS S STAS-ΔIVS) were cloned in-frame into pET52b( þ) (EMD Chemicals) with a C-terminal His 10 -tag. A third STAS-ΔIVS construct encompassing aa 517-738 (hPDS ST STAS-ΔIVS) was cloned into pET28-a( þ) in-frame with an N-terminal His 6 -tag. Digested ligation products were transformed into E. coli BL21(DE3) cells (EMD chemicals). Plasmid sequence integrity was validated by DNA sequencing. Recombinant DNA was quantitated by Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA), and DNA size and purity analyzed by 2% agarose gel.
Expression and isolation of purified hPDS STAS
E.coli BL21(DE3) cells harboring STAS-ΔIVS plasmids in pET52-b( þ) and pET28-a( þ) were grown overnight in LB medium containing kanamycin (30 μg/L). A 20 mL overnight inoculum was added to 2 L LB medium. Cultures were maintained at 37°C until reaching OD 0.6-0.8. Protein expression was then induced by IPTG (empirically optimized at 750 μM) for 16 h at 13°C. Induced cells were harvested by centrifugation (GSA rotor, Sorvall RC5B) at 6000 rpm for 15 min at 4°C, and stored at À 80°C until further use. Harvested cells were freeze-thawed and suspended in buffer A (25 mM Tris-HCl, pH 8.5, 150 mM NaCl, 10 mM imidazole) supplemented with complete protease inhibitor cocktail tablet (Roche), 0.01% PMSF, and lysonase (Novagen) (10 μl/l cell culture), then agitated 30 min at 4°C, and sonicated (Branson digital sonifier, S-450D) at 4°C, 7 Â 7 s cycles at 35% amplitude with 1 min on ice between cycles.
Purification of insoluble STAS-ΔIVS polypeptide
Lysate was centrifuged 30 min at 17,000 rpm at 4°C to separate soluble and insoluble (inclusion body-containing) fractions. SDS-PAGE of preparations from all three STAS-ΔIVS constructs revealed that each accumulated predominantly in inclusion bodies which were washed 3x in buffer A and solubilized in buffer A containing 6 M Guanidine HCl. The cleared, denatured lysate was loaded onto pre-equilibrated Ni-NTA columns (Qiagen). STAS-ΔIVS protein was purified as previously described for Rv1739c STAS [18] , except for inclusion of 2 M urea in wash and elution buffers, and additional modifications described in Supplementary Information. Eluate fractions were evaluated by SDS-PAGE. STAS-ΔIVS-containing fractions were pooled and dialyzed in refolding buffer B (25 mM Tris-HCl, 50 mM NaCl, pH 7.9) at 4°C with three buffer replacements at 12 h intervals. The dialyzed STAS-ΔIVS protein was subsequently purified by anion-exchange chromatography (Q-sepharose fast flow matrix, GE Healthcare, Marlborough, MA). Purified protein was eluted in buffer B with a salt gradient increasing to 1 M NaCl. Q-sepharose eluates were dialyzed in buffer C (25 mM Tris-HCl, 150 mM NaCl, pH 7.9).
Immunoblot analysis was performed with mouse monoclonal anti-(His) 6 antibody (Sigma-Aldrich, EMDMillipore, Billerica, MA) diluted 1:3000. HRP-conjugated secondary antibodies (Sigma-Aldrich) were diluted 1:1000. Proteins were separated on 16% SDS-PAGE. ECL signal was detected with reagents from Amersham Biosciences by Kodak X-omat 2000 A.
Protein purification was assessed by size exclusion chromatography using a Biologic Duo flow FPLC system (Bio-Rad) at 4°C on a Superdex 75 column (Amersham Biosciences) of 125 mL bed volume at 1 mL/min flow-rate, pre-calibrated with molecular weight standards (Bio-Rad) and pre-equilibrated in buffer C. 
MALDI-TOF MS
hPDS ST STAS-ΔIVS protein identity and homogeneity were tested by MALDI-TOF MS by determination of the m/z ratio on an AB/MDS Sciex 4800 Plus MALDI TOF/TOF Analyzer (Applied Biosystems, Carlsbad, CA). His 6 -tagged protein was diluted 1:20 into a solution of standard MALDI matrix sinapinic acid (prepared from 5.0 mg/mL stock), spotted onto the 4800 OptiTOF metal target plate and dried. Data were collected as total ion current (TIC) from 500 laser shots.
CD spectroscopy
Protein folding and intrinsic secondary structural characteristics of recombinant hPDS ST STAS-ΔIVS domain were assessed by Far-UV (260-190 nm) CD measurements at 25°C on a Jasco-810 spectropolarimeter (Tufts University School of Medicine, Boston, MA). Anion exchange chromatography-purified and Buffer C-dialyzed sample was used for CD analysis. Prior to data collection, protein samples were clarified by centrifugation at 13,000 rpm, 1 min, 4°C (Eppendorf 5424 R). Data were collected using a 1 mm path length quartz cuvette (Starna Cells, Atascadero, CA) with 1 nm bandwidth, 2 s response time, 20 nm/min scan speed, and 4 scans in continuous mode. Buffer-corrected spectra were recorded for 23 μM STAS-ΔIVS. Data were converted into Molar Residue Ellipticity (MRE) in units of θ (deg cm 2 dmol À 1 ) and analyzed using the program K2D2 [20] . Data were collected in triplicate and averaged for analysis. with respective spectral widths of 13 ppm and 80 ppm in 1 H and 13 C dimensions. Data were processed on an Intel PC workstation running OpenSuse11.1 using NMRPipe/NMRDraw processing software [23] . A Gaussian filter with a line-broadening parameter of 12 Hz was applied in direct and indirect acquired dimensions. All data sets were zero-filled once in each dimension to yield a final matrix of 2048*256 real data points. All 1 H chemical shift values
Solution NMR spectroscopy
were referenced with respect to internal standard DSS [24] . NMR data were analyzed with NMRDraw [23] and CCPNMR [25] . The hPDS ST STAS-ΔIVS interaction with GDP nucleotide was measured by collecting a series of 2D 1 H- 15 N HSQC experiments of 32 scans.
hPDS ST STAS-ΔIVS (0.25 mM) was titrated with nucleotide to a saturating concentration of 20 mM.
Fluorescence spectroscopy
One native Trp and six native Tyr residues of hPDS ST STAS-ΔIVS served as intrinsic fluorescence intensity probes. STAS protein purified by Ni-affinity-and anion exchange chromatography was used in Buffer C for fluorescence experiments. Samples were centrifuged before use. GDP free acid (Sigma) of highest available purity was prepared as stock solutions in buffer A. hPDS ST STAS-ΔIVS (20) (21) (22) (23) μM; initial volume 200 mL) was preincubated in 48-well plates at 24°C with nucleotide. Steady-state intrinsic fluorescence intensity of hPDS ST STAS-ΔIVS was then recorded at λ em 290-400 nm at 2-nm intervals with fixed λ ex 280 nm (SpectraMax M5, Molecular Devices, Sunnyvale, CA) in the presence of sequentially increasing nucleotide concentration, or titrated with buffer C alone. Protein and ligand were mixed and agitated 15 min prior to data collection. hPDS ST STAS-ΔIVS fluorescence at each nucleotide concentration was corrected for dilution and for inner filter effect (IFE) contributions of added nucleotide, on the intrinsic fluorescence of a mixture of a free tryptophan plus 6 M eq of free tyrosine (the 1:6 Trp: Tyr molar ratio reflected in the native hPDS ST STAS-ΔIVS aa sequence), with identical data acquizition parameters and instrument settings, as described [26] . IFE corrected and normalized fluorescence intensities were plotted as a function of nucleotide concentration and fit (SigmaPlot, Systat) to a single site ligand-binding model to determine dissociation constant (K d ) as described for nucleotide binding by Rv1739c STAS [15] .
Results and discussion
Molecular cloning of hPDS STAS domain
All the primers used in this study are shown in Table 1 . We initially planned NMR structural characterization of hPDS STAS-ΔIVS using two STAS constructs hPDS S (aa 512-743) and hPDS L (aa 512-780) as shown in Fig. 1 . Empirical testing of these STAS-ΔIVS constructs revealed low protein yields with high tendency to precipitate during dialysis for imidazole removal (see below). In view of the potentially destabilizing role of N-terminal Arg 512 of the above STAS constructs, we generated hPDS ST STAS-ΔIVS constructs in pET-52b( þ) and in pET28a( þ ) (Supplementary Fig. S1 ) that preserved the predicted secondary structure of the longer constructs (see Supplementary Fig. S2 ).
Expression and isolation of hPDS STAS domain
Growth and induction of E. coli expressing STAS-ΔIVS polypeptides hPDS L , hPDS S , and hPDS ST respectively yielded 3.6, 3.3, Table 1 Primer sequences used in PCR amplifications of IVS excluded regions of hPDS STAS. Mutagenesis primers #1-5 were to amplify STAS-ΔIVS sequences for cloning hPDS L and hPDS S constructs into pET52b. Primers #6 and 7 were used to shuttle hPDS ST STAS sequence (excluding disordered IVS region) from pET52b( þ ) into pET28a(þ ) for structural studies.
SLC26A4 STAS
Primer sequence 1. mut_For 5′-GACTGTGACCTTGCCATGGCGAGAGTTCAGTTTCCTTCTTGG-3′ 2. mut_Rev 5′-GCGTGGCACCAGAGCGAGCTCGGATGCAAGTGTACGCATAGC-3′ 3. mut_Rev-short
5′-GCGTGGCACCAGAGCGAGCTCTAAAATGGAACCTTGACCCTC-3′
4. mutfuse_Rev 5′-GCACAAGGCTATGGATTGGCACGGCATCAAATCCAACTGTGGAC-3′
mutfuse_For
5′-GTCCACAGTTGGATTTGATGCCGTGCCAATCCATAGCCTTGTGC-3′
6. 28a_For 5′-TCACATATGGCTAGCTCTTGGAATGGCCTTGGAAGC-3′ 7. 28a_Rev 5′-CAGGAGCTCGAATTCCTAACCCTCTTGAGATTTCACTTG-3′ and 3.3 g wet cell paste per liter culture. SDS-PAGE revealed bands of expected size (in kDa) for hPDS L (24.3), hPDS S (20.1) (data not shown), and for hPDS ST (18.8; Fig. 2A ). Protein induction was more efficient at 13°C than at 25°C or 37°C. Polypeptide products of each construct partitioned 95% into the insoluble fraction.
Inclusion body lysates were bound to Ni-NTA beads, and eluted with imidazole step gradients. Yields of eluted of STAS-ΔIVS polypeptide were 28% for hPDS L , 21% for hPDS S, and 53% hPDS ST. The larger imidazole-resistant retained fractions of STAS-ΔIVS constructs hPDS L and hPDS S were not released even upon addition of $ 0.1% (w/v) octyl glucoside (OG) or dodecyl maltoside (DM). Moreover, as much as 88% of initially soluble Ni-NTA-purified STAS-ΔIVS constructs hPDS L and hPDS S precipitated during dialysis. The remaining soluble protein was too unstable to allow completion of CD experiments. Purification in buffers containing OG or DM marginally improved protein yield, but CD spectra of these preparations revealed absence of well-folded protein (not shown). We therefore focused subsequent efforts on purification and characterization of hPDS ST STAS-ΔIVS (see Supplementary  Table. S1 ). All the data presented below are from this construct. Immunoblot of samples in near physiologic salt concentration demonstrated both monomeric and dimeric forms of hPDS ST STAS-ΔIVS (Fig. 2B) , with some higher order oligomers. hPDS ST STAS-ΔIVS exhibited less precipitation during dialysis (o23%) than did larger STAS-ΔIVS polypeptides. Size exclusion chromatography revealed oligomeric forms of protein in solution, corroborating the immunoblot data.
Protein fractionated by size exclusion chromatography was subjected to dialysis for subsequent anion exchange chromatographic purification, with o7% precipitation during dialysis. Reducing SDS-PAGE of 1 M NaCl eluates from anion exchange chromatography revealed only monomers, suggesting that high salt can shift the conformational equilibrium towards the monomeric state (Fig. 2C) . Reducing [NaCl] to r150 mM restored oligomeric heterogeneity. Maintaining [NaCl]Z500 mM reliably reduced oligomerization of hPDS ST STAS-ΔIVS.
Yields of His6-tag-free STAS hPDS ST polypeptide
His 6 tag removal from the STAS-ΔIVS polypeptides led to major protein loss ( o25% recovery). Tag-free samples exhibited moderate precipitation at later stages of purification, and resulting sample quantities were insufficient for 1D 1 H NMR studies. Therefore, further attempts to optimize purification of His-tag-free STAS-ΔIVS polypeptides were discontinued.
MALDI-TOF MS
Mass spectrometry of hPDS ST STAS in buffers lacking reducing agent was not successful. Data collected in sample buffers containing Z 9 mM tris-carboxyethylphosphine resulted in mass detection of potassiated monomeric and dimeric species of protein (Fig. 2D) , accompanied by 2 forms of uncertain oligomeric stoichiometry. Fig. 2E shows the CD spectrum of hPDS ST STAS-ΔIVS. The data show secondary structural elements suggesting a folded conformation in solution. The characteristic double ellipticity minima at 208 and 220 nm are diagnostic for helical structure. The spectral lineshape pattern, including the noted ellipticity differences at the two minima, shows the presence of β-strand structure. Spectral deconvolution analysis predicts that secondary structural elements constitute $ 41% of the polypeptide. Correcting for the His6-fusion tag at the N-terminus, the measured % secondary structure is close to that predicted ( $ 46%) from the hPDS ST STAS-ΔIVS model built on the rat prestin STAS-ΔIVS template. These results show that purified, recombinant hPDS ST STAS-ΔIVS polypeptide refolded from inclusion body lysate adopts a well folded, structured conformation in solution.
CD spectroscopy
NMR spectroscopy of hPDS ST STAS domain
The folded state of hPDS STAS was further examined by applying 1D 1 H and 2D heteronuclear solution NMR methods (Fig. 3) . First we attempted 2D (Fig. 3B) , which for an intrinsically disordered or unfolded/partially folded protein would shrink to a Table S3) shows complete crosspeak dispersion similar to that of the longer acquizition time spectrum. Maintenance of spectral quality during 1 week of sample storage suggests stability of protein conformation at 0.25 mM during this time.
The expected number of 1 H-
15
N backbone correlation crosspeaks for this construct (Fig. S1) is 162, including 23 1 H- 15 N correlation crosspeaks predicted to arise from the N-terminal cleavable (His) 6 -fusion tag. The 156 crosspeaks detected in the spectrum likely include all or most core protein resonances. Two sets of crosspeaks of different intensity distributions were present in the spectrum. The predominant set of $130 crosspeaks shows moderately sharper linewidths, whereas, the minority set of $ 26 crosspeaks has broader linewidths of intensity at least 50% lower than the average intensity of the majority set of crosspeaks. These differences in linewidth might reflect different dynamic properties elicited by the respective resonances. The weaker intensity crosspeaks could include some or all H NMR data. These data together suggest that hPDS ST STAS-ΔIVS adopts a folded conformation in solution.
NMR detection of nucleotide binding by hPDS ST STAS
The nucleotide-binding properties of anti-s factor antagonist SpoIIAA [27] , STAS domain of Rv1739c from M. tuberculosis [15] , and STAS domains from full-length YchM/DauA [12] prompted evaluation of nucleotide binding by hPDS ST STAS-ΔIVS.
We first tested stability of NMR samples by collecting a series of 2D Fig. 5A and B) probably reflecting nucleotide-induced stabilization of normally undetected, flexible residues, and/or slow conformational exchange of select residues in their local environments. These analyses suggest that GDP binding induces CSP of select protein residues, a process that occurs at faster-intermediate NMR time scales. Taken together, these results strongly suggest that hPDS ST STAS-ΔIVS binds guanine nucleotide.
Nucleotide binding by hPDS ST STAS-ΔIVS by intrinsic fluorescence quench
The presence in hPDS ST STAS-ΔIVS (Fig. 1 ) of a single Trp residue, Trp518, and 6 Tyr residues (Tyr530, Tyr536, Tyr556, Tyr691, Tyr698, and Tyr728) allowed assessment of nucleotide binding by intrinsic fluorescence quench. hPDS ST subjected to 280 nm excitation exhibited a fluorescence emission λ max of 320 nm. Fig. 6A illustrates the gradual quench of intrinsic STAS fluorescence with progressively increasing concentrations of GDP, with maximum observed quench of 14.2%. The observed quench isotherm is compatible with a single nucleotide binding site of K 1⁄2 ¼ 178781 μM (Fig. 6B) . The data suggest a nucleotide interaction surface in STAS domain that directly or indirectly perturbs Trp and/or Tyr residues through conformational effects on adjacent or interposed residues. These results are consistent with the heteronuclear NMR data showing nucleotide binding by hPDS ST STAS-ΔIVS. Similar future experiments will examine nucleotide binding of full-length wild type and disease-associated mutants, and define the nucleotide binding surface of the protein. Preliminary data (Sharma et al., unpublished) confirm nucleotide binding by the recombinant full-length STAS domain of A. thaliana sulfate transporter SULTR1;2, further strengthening the hypothesis that STAS domains are nucleotide binding proteins [4] .
The tendency of hPDS ST STAS-ΔIVS to aggregate was modulated by salt concentration and pH. Buffer conditions of Z500 mM NaCl and pH 6.2 each reduced protein aggregation. At 150 mM NaCl, the protein exhibited a similar monomer-dimer equilibrium at both pH 6.2 and pH 7.9. SLC26A/SulP proteins in solution are known to exhibit dimeric and higher order oligomeric structures [2, 12, 28] . Rat Prestin STAS-ΔIVS exhibited dimers and tetramers in solution with a tendency toward formation of higher molecular weight aggregates [29] . Recombinant mouse Slc26a9 STAS also exhibited a monomerdimer equilibrium [30] . Protein aggregation was noted for E. coli DauA STAS domain variants harboring mutations at the sites homologous to the disease-associated mutations in SLC26 STAS domains [31] . Future studies will test the role of the three Cys residues of hPDS STAS (aa 565, 662, and 706) in STAS oligomerization. Rat prestin STAS template-based modeling of hPDS STAS-ΔIVS suggests occupancy of flexible loop positions by the three homologous Cys residues (Cys706 is the first residue in helix α3) with side chain exposure to the solvent environment ( Supplementary Fig. S4 ). Thus, alterations in solvent pH, salt concentration, and redox environment may influence the native cysteine-cystine equilibrium, including possible inter-monomer cystine linkage.
IVS deletion from the hPDS STAS domain has allowed a reproducible purification protocol, yielding well-folded protein in quantities suitable for NMR structural studies. Attempts are currently underway to purify full-length hPDS STAS domain polypeptide from soluble fractions in quantity sufficient for solution NMR, using solubility-enhancing fusion tags. However, the present study shows that the IVS region is dispensable for nucleotide binding by hPDS STAS.
Conclusions
The class of eukaryotic STAS domains from rodent and human SLC26 transporters has proven difficult to express in a well-folded conformation at the high concentrations required for structural studies. With the exception of rat SLC26A5/prestin, only one 1 H- 15 N 2D HSQC spectrum has been reported from a mammalian STAS domain (SLC26A3). However no structural information has been reported for SLC26A3 STAS domain, perhaps reflecting low sample solubility [8] , or for STAS domain from any human member. Here we have presented data on the molecular cloning, expression and purification, and protein folding characterization of hPDS ST STAS-ΔIVS as characterized by CD and by 1D and 2D heteronuclear NMR. Our purification protocol has yielded well-folded U- 13 C/ 15 N labeled recombinant STAS in the milligram quantities sufficient for future unambiguous NMR residue assignment and elucidation of three dimensional structure of this deafness gene product, SLC26A4/pendrin. We found that hPDS ST STAS-ΔIVS exists in solution in monomer and dimer states, with propensity to higher-order oligomerization. We showed by intrinsic fluorescence quench and by CSP NMR methods that hPDS STAS-ΔIVS can bind GDP. These results are of importance not only for structure/function studies of hPDS STAS, but may in addition be applicable to STAS domains of other human SLC26 anion transporter polypeptides. This information will increase our understanding of a known therapeutic target for treatment of congenital deafness. It will also increase understanding of an underappreciated major pathway for distal nephron chloride reabsorption representing an important target for diuretic development, with implications for enhanced management of fluid overload in settings of trauma and intensive care, and in chronic cardiac, renal, and liver diseases. 
